Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Theravance Inc (THRX)    
$17.13 0.54 (3.03%) as of 4:30 Fri 4/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 110,543,000 as of 6/30
Market Cap: 1.89(B)
Last Volume: 689,177 Avg Vol: 874,376
52 Week Range: $10.68 - $30.4
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Biotechnology

Member Indexes:

      

Rankings:

     
Insider 3 Months    : 41.2
Insider 6 Months    : 41.4
Insider 3/6 Months : 83.1
Guru Rank Number :  94
Guru Rank Value     : 9.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. Co. is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system / pain. Co.'s key programs include: RELVAR™ or BREO™ (fluticasone furoate/vilanterol), ANORO™ (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 92,674 925,130 1,415,551 5,146,223
Total Buy Value $2,147,483,647 $2,147,483,647 $2,147,483,647 $2,147,483,647
Total People Bought 1 1 1 1
Total Buy Transactions 1 2 4 8
Total Shares Sold 0 0 81,580 729,358
Total Sell Value $0 $0 $1,825,039 $24,389,744
Total People Sold 0 0 2 6
Total Sell Transactions 0 0 3 15
End Date 2015-01-18 2014-10-17 2014-04-18 2013-04-18

   
Records found: 454
  Page 1 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Glaxosmithkline Plc 10% Owner   –       –       •   2015-03-02 4 B $1,673,690.00 $2,147,483,647 I/I 92,674 31,673,853 1.5 -11%     
   Aguiar Michael W President & CEO   •       •      –    2015-02-20 4 D $18.22 $123,696 D/D (6,789) 446,148     -
   Witek Theodore L Jr Sr. VP, Corp Partnerships   •       –      –    2015-01-07 4 A $0.00 $0 D/D 71,429 71,429     -
   Desparbes Eric SVP and CFO   •       –      –    2015-01-07 4 A $0.00 $0 D/D 36,972 139,443     -
   Aguiar Michael W President & CEO   •       •      –    2015-01-07 4 A $0.00 $0 D/D 176,056 464,896     -
   Abercrombie George B Sr. VP, Corp. Partnerships   •       –      –    2015-01-07 4 A $0.00 $0 D/D 71,429 81,429     -
   Friedman Cathy Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 6,500 21,670     -
   Tyree James L Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 6,500 21,670     -
   Pepe Paul Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 6,500 21,670     -
   Waltrip William H Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 3,250 103,314     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2014-11-04 4 B $12,786,500.00 $2,147,483,647 I/I 832,456 31,581,179 1.5 21%     
   Kearney Terrence C Director   –       •      –    2014-10-30 4 A $0.00 $0 D/D 23,133 23,133     -
   Desparbes Eric SVP and CFO   •       –      –    2014-10-16 4 A $0.00 $0 D/D 102,471 102,471     -
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 262,198     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 334,040     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 443,013     -
   Blum Leonard M Sr VP, Chief Comm. Officer   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 401,538     -
   Winningham Rick E Director   –       •      –    2014-08-15 4 D $0.00 $0 D/D (96,250) 825,391     -
   Aguiar Michael W President & CEO   •       •      –    2014-08-15 4 A $0.00 $0 D/D 43,905 288,840     -
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-08-13 4 S $22.50 $1,202,040 D/D (53,424) 265,459 45%     
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-08-13 4 OE $9.81 $926,264 D/D 74,441 318,883     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-12 4 S $22.30 $23,370 D/D (1,048) 446,274 45%     
   Glaxosmithkline Plc 10% Owner   –       –       •   2014-08-11 4 B $3,912,270.00 $2,147,483,647 I/I 172,651 30,748,723 1.5 -45%     
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-11 4 OE $14.53 $489,182 D/D 33,667 474,430     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-11 4 S $22.12 $599,629 D/D (27,108) 447,322 45%     

  454 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed